Jennifer Doudna Sells 676 Shares of Tempus AI (NASDAQ:TEM) Stock

Tempus AI, Inc. (NASDAQ:TEM) Director Jennifer Doudna sold 676 shares of the business’s stock in a transaction dated Monday, December 1st. The shares were sold at an average price of $75.55, for a total value of $51,071.80. Following the completion of the sale, the director owned 23,952 shares in the company, valued at approximately $1,809,573.60. This trade represents a 2.74% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Tempus AI Price Performance

Shares of NASDAQ TEM opened at $76.33 on Friday. The company has a current ratio of 3.28, a quick ratio of 3.12 and a debt-to-equity ratio of 2.45. The firm has a market cap of $13.58 billion, a P/E ratio of -64.14 and a beta of 4.99. The business’s 50 day moving average is $82.12 and its 200-day moving average is $72.84. Tempus AI, Inc. has a 1-year low of $31.36 and a 1-year high of $104.32.

Tempus AI (NASDAQ:TEM) last issued its quarterly earnings data on Tuesday, November 4th. The company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.16) by $0.05. Tempus AI had a negative net margin of 18.45% and a negative return on equity of 73.21%. The business had revenue of $334.21 million during the quarter, compared to analysts’ expectations of $328.89 million. During the same quarter in the previous year, the company earned ($0.46) EPS. The business’s revenue was up 84.7% on a year-over-year basis. Equities research analysts predict that Tempus AI, Inc. will post -6.15 earnings per share for the current year.

Hedge Funds Weigh In On Tempus AI

Institutional investors and hedge funds have recently modified their holdings of the business. Vanguard Group Inc. boosted its stake in Tempus AI by 6,247.5% during the 1st quarter. Vanguard Group Inc. now owns 5,995,117 shares of the company’s stock valued at $289,204,000 after purchasing an additional 5,900,668 shares during the last quarter. Jump Financial LLC purchased a new stake in shares of Tempus AI in the first quarter valued at about $8,545,000. Tyler Stone Wealth Management bought a new position in shares of Tempus AI during the first quarter valued at about $386,000. Salem Investment Counselors Inc. lifted its position in shares of Tempus AI by 8,020.0% during the second quarter. Salem Investment Counselors Inc. now owns 30,450 shares of the company’s stock valued at $1,935,000 after purchasing an additional 30,075 shares in the last quarter. Finally, Russell Investments Group Ltd. bought a new stake in Tempus AI during the first quarter worth $260,000. 24.22% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

TEM has been the subject of a number of analyst reports. TD Cowen downgraded Tempus AI from a “buy” rating to a “hold” rating and set a $88.00 price target for the company. in a research note on Tuesday, October 21st. BTIG Research upped their price objective on Tempus AI from $96.00 to $105.00 and gave the stock a “buy” rating in a research report on Tuesday, November 25th. Morgan Stanley raised their price objective on Tempus AI from $80.00 to $85.00 and gave the company an “overweight” rating in a research note on Monday. Piper Sandler dropped their target price on shares of Tempus AI from $105.00 to $80.00 and set a “neutral” rating for the company in a report on Tuesday, November 11th. Finally, Cowen downgraded shares of Tempus AI from a “buy” rating to a “hold” rating in a research note on Tuesday, October 21st. Seven investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $81.17.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.